Vaginal microbicides: A novel approach to preventing sexual transmission of HIV

被引：17

作者：

Doncel G. ^{[1
]}

Mauck C. ^{[1
]}

机构：

[1] CONRAD, Eastern Virginia Medical School, 601 Colley Avenue, Norfolk, 23507, VA

来源：

Current HIV/AIDS Reports | 2004年 / 1卷 / 1期

关键词：

Bacterial Vaginosis; Human Immunodeficiency Virus; Human Immunodeficiency Virus Infection; Human Immunodeficiency Virus Transmission; Human Immunodeficiency Virus Type;

D O I：

10.1007/s11904-004-0004-0

中图分类号：

学科分类号：

摘要：

The AIDS epidemic continues its unrelentless expansion. According to the Joint United Nations Programme on HIV/AIDS, there are more than 40 million people living with HIV, and more than 15,000 new infections occur every day. One approach to curbing HIV is the development of topical microbicidal agents or microbicides. These are compounds designed to protect the body’s mucosal surfaces from infection by sexually transmitted diseasecausing pathogens, including HIV. Several candidates are in preclinical stages; however, only a handful have been tested in humans for safety, and even fewer are ready for clinical efficacy trials. In this update, we describe microbicide research and development, including preclinical screening algorithms, ideal properties, compounds in the pipeline, and future prospects. This review is based on a previous work, which has been updated to contain new information, especially regarding microbicide candidates in preclinical and clinical stages of development. © 2004, Current Science Inc.

引用

页码：25 / 32

页数：7

共 61 条

[1]

Moodley P., Connolly C., Sturm A.W., Interrelationships among human immunodeficiency virus type 1 infection, bacterial vaginosis, trichomoniasis, and the presence of yeasts, J Infect Dis, 185, pp. 69-73, (2002)

[2]

Miller C.J., Shattock R.J., Target cells in vaginal HIV transmission, Microbes Infect, 5, pp. 59-67, (2003)

[3]

Wu Z., Chen Z., Phillips D.M., Human genital epithelial cells capture cell-free human immunodeficiency virus type 1 and transmit the virus to CD4+ cells: implications for mechanisms of sexual transmission, J Infect Dis, 188, pp. 1473-1482, (2003)

[4]

Pierson T.C., Doms R.W., HIV-1 entry inhibitors: new targets, novel therapies, Immunol Lett, 85, pp. 113-118, (2003)

[5]

Kreiss J., Ngugi E., Holmes K., Et al., Efficacy of nonoxynol-9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes, JAMA, 268, pp. 477-482, (1992)

[6]

Roddy R.E., Zekeng L., Ryan K.A., Et al., A controlled clinical trial of nonoxynol-9 film to reduce male-to-female transmission of sexually transmitted diseases, N Engl J Med, 339, pp. 504-510, (1998)

[7]

Stephenson J., Widely used spermicide may increase, not decrease risk of HIV transmission, JAMA, 284, (2000)

[8]

Van Damme L., Ramjee G., Alary M., Et al., Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial, Lancet, 360, pp. 971-977, (2002)

[9]

Chantler E., New and existing spermicides with virucidal properties, Heterosexual Transmission of AIDS, (1990)

[10]

Corner A.M., Dolan M.M., Yankell S.L., Et al., C31G, a new agent for oral use with potent antimicrobial and antiadherence properties, Antimicrob Agents Chemother, 32, pp. 350-353, (1998)

← 1 2 3 4 5 6 7 →